The role of stem cell markers in choriocarcinoma: Immunocytochemical analysis in JAR cell line

Year 2025, Volume: 39 Issue: 1, 23 - 30, 12.03.2025

H. Seda Vatansever

Abstract

Objective: Choriocarcinoma is a type of cancer that originates from placental trophoblastic tissue and has a high malignant potential. The aim of this study was to investigate the distribution of stem cell and cancer stem cell markers in the JAR cell line. The study is to provide information about the biology of choriocarcinoma and the mechanisms of resistance to treatment.

Materials and Methods: JAR cells were cultured in RPMI 1640 culture medium. Colony formation assay was performed in JAR cells. The expression of OCT3/4, CD133, C-KIT, SALL4 and CD90 markers were analysed using indirect immunoperoxidase method. Healthy endometrial epithelial cell line RL95-2 was used for statistical analysis.

Results: JAR cells showed statistically high colony formation efficiency compared to the RL95-2 group. Immunocytochemical analyses showed strong immunoreactivity for CD133 and moderate immunoreactivity for SALL4. C-KIT, OCT3/4 and CD90 showed weak immunoreactivity.

Conclusion: The JAR cell line has emerged as a valuable model for trophoblastic cell invasion and placentation studies in choriocarcinoma. Markers such as CD133 and SALL4 provide important information about stem cell-like characteristics and choriocarcinoma malignancy. Lower expressions of C-KIT, OCT3/4 and CD90 reflect heterogeneous stem cell profiles in JAR cells. This diversity provides important insights into the complex nature of choriocarcinoma stem cells and sheds light on potential therapeutic approaches.

Keywords: Choriocarcinoma, JAR cell line, stem cell markers, cancer stem cells, trophoblastic malignancy.

Keywords

Keywords: Choriocarcinoma, JAR cell line, stem cell markers, cancer stem cells, trophoblastic malignancy.

References

• 1. Mancarella S, Serino G, Gigante I et al. CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype. J Exp Clin Cancer Res, 2022; 41: 65.
• 2. Silva IA, Bai S, McLean K et al. Aldehyde Dehydrogenase in Combination With CD133 Defines Angiogenic Ovarian Cancer Stem Cells That Portend Poor Patient Survival. Cancer Research, 2011; 71: 3991-4001.
• 3. Nomura A, Banerjee S, Chugh R et al. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Oncotarget, 2015; 6: 8313-22.
• 4. Zhang L, Xu Z, Xu X et al. SALL4, a Novel Marker for Human Gastric Carcinogenesis and Metastasis. Oncogene, 2013; 33: 5491-5500.
• 5. Tulake W, Yuemaier R, Sheng L et al. Upregulation of Stem Cell Markers ALDH1A1 and OCT4 as Potential Biomarkers for the Early Detection of Cervical Carcinoma. Oncology Letters, 2018;
• 6. Yan B, Mu Y, Cui M and Liu L. Clinicopathological Significance and Prognostic Implication of CD44 and Its Splice Variants (V3 and V6) in Colorectal Cancer. Translational Cancer Research, 2020; 9: 1215-1224.
• 7. Zhang K, Che S, Pan C et al. The SHH/Gli axis regulates CD90-mediated liver cancer stem cell function by activating the IL6/JAK2 pathway. J Cell Mol Med, 2018; 22: 3679-3690.
• 8. Klein-Rodewald T, Micklich K, Sanz-Moreno A et al. New C3H KitN824K/WT Cancer Mouse Model Develops Late-Onset Malignant Mammary Tumors With High Penetrance. Scientific Reports, 2022; 12:
• 9. Foster BM, Shi L, Harris KS et al. Bone Marrow-Derived Stem Cell Factor Regulates Prostate Cancer-Induced Shifts in Pre-Metastatic Niche Composition. Frontiers in Oncology, 2022; 12:
• 10. Zhang X, Zhang P, Shao M et al. SALL4 Activates TGF-β/SMAD Signaling Pathway to Induce EMT and Promote Gastric Cancer Metastasis. Cancer Management and Research, 2018; Volume 10: 4459-4470.
• 11. Sun J, Zhao Z, Zhang W et al. Spalt-Like Protein 4 (SALL4) Promotes Angiogenesis by Activating Vascular Endothelial Growth Factor a (VEGFA) Signaling. Medical Science Monitor, 2020; 26:
• 12. Forghanifard MM, Moghbeli M, Raeisossadati R et al. Role of SALL4 in the Progression and Metastasis of Colorectal Cancer. Journal of Biomedical Science, 2013; 20: 6.
• 13. Yang M, Xie X and Ding Y. SALL4 Is a Marker of Poor Prognosis in Serous Ovarian Carcinoma Promoting Invasion and Metastasis. Oncology Reports, 2016; 35: 1796-1806.
• 14. Yu W, Liu F, Lei Q et al. Identification of Key Pathways and Genes Related to Immunotherapy Resistance of LUAD Based on WGCNA Analysis. Frontiers in Oncology, 2022; 11:
• 15. Lobba ARM, Carreira ACO, Cerqueira OLD et al. High CD90 (THY-1) Expression Positively Correlates With Cell Transformation and Worse Prognosis in Basal-Like Breast Cancer Tumors. Plos One, 2018; 13: e0199254.
• 16. Kumar A, Bhanja A, Bhattacharyya J and Jaganathan BG. Multiple Roles of CD90 in Cancer. Tumor Biology, 2016; 37: 11611-11622.
• 17. Wu A, Oh S, Wiesner SM et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev, 2008; 17: 173-84.
• 18. Kawamoto H, Yuasa T, Kubota Y et al. Characteristics of CD133(+) human colon cancer SW620 cells. Cell Transplant, 2010; 19: 857-64.